Top

Published in:

01-07-2013 | Review Article

Living donor liver transplantation for hepatitis C

Authors: Yasutsugu Takada, Shinji Uemoto

Published in: Surgery Today | Issue 7/2013

Abstract

Liver cirrhosis and hepatocellular carcinoma related to chronic hepatitis C virus (HCV) infection are currently the most common indications for liver transplantation. The number of living donor liver transplantation (LDLT) procedures has increased given the shortage of donor organs from deceased donors. However, recurrence of HCV infection is universal and affects graft survival. This mini-review compared the outcomes for HCV-positive recipients after LDLT with those after deceased donor liver transplantation.

Adam R, McMaster P, O’Grady JG, Castaing D, Klempnauer JL, Jamieson N, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl. 2003;9:1231–43.PubMedCrossRef

Wiesner RH, Sorrell M, Villamil F, International Liver Transplantation Society Expert Panel. Report of the first international liver transplantation society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl. 2003;9:S1–9.PubMedCrossRef

The Japanese Liver Transplantation Society. Liver transplantation in Japan—Registration by the Japanese Liver Transplantation Society (in Japanese with English abstract). Ishoku 2010;45:621–32.

Eguchi S, Soyama A, Hidaka M, Takatsuki M, Muraoka I, Tomonaga T, et al. Liver transplantation for patients with human immunodeficiency virus and hepatitis C virus coinfection with special reference to hemophiliac recipients in Japan. Surg Today. 2011;41:1325–31.PubMedCrossRef

Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl. 2003;9:S28–34.PubMedCrossRef

Prieto M, Berenguer M, Rayon J, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in HCV genotype 1b following transplantation. Hepatology. 1999;29:250–6.PubMedCrossRef

Berenguer M, Prieto M, Juan FS, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology. 2002;36:202–10.PubMedCrossRef

Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol. 2005;42:448–56.PubMedCrossRef

Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, et al. Long-term outcome of liver transplantation for chronic hepatitis C: a 10-year follow-up. Transplantation. 2004;77:226–31.PubMedCrossRef

10.

Velidedeoglu E, Mange KC, Frank A, Abt P, Desai NM, Markmann JW, et al. Factors differentially correlated with the outcome of liver transplantation in HCV+ and HCV− recipients. Transplantation. 2004;77:1834–42.PubMedCrossRef

11.

Gaglio PJ, Malireddy S, Russo M, Lapointe-Rudow D, Emond JC, Brown RS. Hepatitis C recurrence in recipients of grafts from living vs cadaveric liver donors [abstract]. Hepatology. 2002;36:265A.

12.

Ghobrial RM, Amersi F, Farmer DG, Chen P, Anselmo DM, Baquerizo A, et al. Rapid and severe early HCV recurrence following adult living donor liver transplantation [abstract]. Am J Transplant. 2002;2:163A.

13.

Gaglio PJ, Malireddy S, RusLevitt BS, Lapointe-Rudow D, Lefkowitch J, Kinkhabwala M, et al. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl. 2003;9:1028–35.PubMedCrossRef

14.

Thuluvath PJ, Yoo HY. Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor liver transplantation. Liver Transpl. 2004;10:1263–8.PubMedCrossRef

15.

Schiano TD, Gutierrez JA, Walewski JL, Fiel MI, Cheng B, Bodenheimer H, et al. Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology. 2005;42:1420–8.PubMedCrossRef

16.

Garcia-Retortillo M, Forns X, Llovet JM, Navasa M, Feliu A, Massaguer A, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology. 2004;40:699–707.PubMedCrossRef

17.

Zimmerman MA, Trotter J. Living donor liver transplantation in patients with hepatitis C. Liver Transpl. 2003;9:S53–7.CrossRef

18.

Russo MW, Shrestha R. Is severe recurrent hepatitis C more common after adult living donor liver transplantation? Hepatology. 2004;40:524–6.PubMedCrossRef

19.

Russo MW, Galanko J, Beavers K, Fried MW, Shrestha R. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl. 2004;10:340–6.PubMedCrossRef

20.

Shiffman ML, Stravitz RT, Contos MJ, Mills AS, Sterling RK, Luketic VA, et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl. 2004;10:1248–55.PubMedCrossRef

21.

Humar A, Horn K, Kalis A, Glessing B, Payne WD, Lake J. Living donor and split-liver transplants in hepatitis C recipients: does liver regeneration increase the risk for recurrence? Am J Transplant. 2005;5:399–405.PubMedCrossRef

22.

Guo L, Orrego M, Rodriguez-Luna H, Balan V, Bayrne T, Chopra K, et al. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transpl. 2006;12:560–5.PubMedCrossRef

23.

Terrault NA, Shiffman ML, Lok ASF, Saab S, Tong L, Brown RS, et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl. 2007;13:122–9.PubMedCrossRef

24.

Schmeding M, Neumann UP, Puhl G, Bahra M, Neuhaus R, Neuhaus P. Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients. Liver Transpl. 2007;13:687–92.PubMedCrossRef

25.

Gallegos-Orozco JF, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, et al. Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course. Liver Transpl. 2009;15:1872–81.PubMedCrossRef

26.

Jain A, Singhal A, Kashyap R, Safadjou S, Ryan CK, Orloff MS. Comparative analysis of hepatitis C recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up. Transplantation. 2011;92:453–60.PubMedCrossRef

27.

Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl. 2008;14(Suppl 2):S58–66.PubMedCrossRef

28.

Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49:274–87.PubMedCrossRef

29.

Kuo A, Terrault NA. Management of hepatitis C in liver transplant recipients. Am J Transplant. 2006;6:449–56.PubMedCrossRef

30.

Kishi Y, Sugawara Y, Akamatsu N, Kaneko J, Tamura S, Kokudo N, et al. Splenectomy and preemptive interferon therapy for hepatitis C patients after living-donor liver transplantation. Clin Transplant. 2005;19:769–72.PubMedCrossRef

31.

Takada Y, Haga H, Ito T, Nabeshima M, Ogawa K, Kasahara M, et al. Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients. Transplantation. 2006;81:350–4.PubMedCrossRef

32.

Tamura S, Sugawara Y, Yamashiki N, Kaneko J, Kokudo N, Makuuchi M. Pre-emptive antiviral therapy fin living donor liver transplantation for hepatitis C: observation based on a single-center experience. Transpl Int. 2010;23:580–8.PubMedCrossRef

33.

Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Fukuhara T, Kotoh K, et al. The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hepatitis C. Transplant Proc. 2009;41:4246–52.PubMedCrossRef

34.

Takada Y, Ueda Y, Uemoto S. Long-term outcomes for HCV-positive patients after living donor liver transplantation [abstract]. Liver Transpl. 2010;16(Supplement 1):S89.

35.

Ueda Y, Takada Y, Marusawa H, Egawa H, Uemoto S, Chiba T. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation. Transplantation. 2010;90:661–5.PubMedCrossRef

36.

Sugawara Y, Tamura S, Yamashiki N, Kaneko J, Aoki T, Sakamoto Y, et al. Preemptive antiviral treatment for hepatitis C virus after living donor liver transplantation. Transpl Proc. 2012;44:791–3.CrossRef

Title: Living donor liver transplantation for hepatitis C
Authors: Yasutsugu Takada
Shinji Uemoto
Publication date: 01-07-2013
Publisher: Springer Japan
Published in: Surgery Today / Issue 7/2013
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI: https://doi.org/10.1007/s00595-012-0361-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Living donor liver transplantation for hepatitis C

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2013

A novel technique for relieving anastomotic tension using halo-vest immobilization after tracheal sleeve resection

Trial using pig cells with the H–D antigen knocked down

An internal hernia projecting through a mesenteric defect following laparoscopic-assisted partial resection of the transverse colon to the lesser omental cleft: report of a case

Diffusely infiltrative squamous cell carcinoma of the esophagus presenting diagnostic difficulty: report of a case

Left ventricular noncompaction complicated by mitral valve prolapse: report of a case

The use of the LigaSure device and the Stapler in closure of the small bowel: a comparative ex vivo study